Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLOR-ACS: Colchicine in Acute Coronary Syndrome
NCT05250596Phase 2Completed
- Sponsor
- Azienda USL Toscana Centro
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of colchicine in Non-ST-elevation acute coronary syndrome (NSTE-ACS) (2 arms), sponsored by Azienda USL Toscana Centro. Primary endpoint: High sensitivity C reactive protein change. Started Feb 2022; status: completed.
02
Drugs
colchicine
03
Conditions
Non-ST-elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT05250596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05250596.